Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.

 

CURRENTLY ENROLLING CLINICAL TRIALS

HOLLYWOOD NEUROLOGY
To participate or refer a patient, please call 954-366-0277.

Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC

Revance-ASPEN: Cervical Dystonia – A randomized double blind study with an injectable investigational medication for Isolated Cervical Dystonia.  After the initial treatment, patients can enter an Open Label Extension for 52 weeks.

Revance JUNIPER: Upper Limb Spasticity – A randomized double blind study with an injectable investigational medication for upper limb spasticity after a stroke or Traumatic Brian Injury, ages 18-70.

Eisai-CLARITY: Early Alzheimer’s Disease – An 18-month randomized study to evaluate the safety and efficacy of an infused investigational medication vs. placebo in subjects 50-90 years of age with Mild Cognitive Impairment or early Alzheimer’s Disease. Visits are every 2 weeks, must have a study partner. 2-year Open label extension to follow for patients completing the double-blind study. (MMSE 22-30)

T3D PIONEER: Mild to moderate Alzheimer’s Disease – A 28-week randomized study to evaluate the efficacy, safety and tolerability of an oral investigational medication vs. placebo in subjects with mild to moderate Alzheimer’s Disease, must have a study partner, ages 50-90. (MMSE 16-26)

Impax: Parkinson’s Disease – A Randomized controlled study to compare the safety and efficacy of an oral drug with Immediate Release-Carbidopa-Levodopa in Parkinson’s disease patients with motor fluctuations.

Neuraly: Early Parkinson’s Disease – A 36-week randomized double-blind study to evaluate the efficacy, safety and tolerability of an oral medication vs. placebo in Early Parkinson’s Disease, ages 30-80.

 

SUNRISE OFFICE NEUROLOGY
To participate or refer a patient Call 954-475-8171, ext 146 (Fanny) or ext 138 (Adriana)

Clinical Coordinators: Fanny Gully, CRC and Adriana Araujo, CRC

Roche – GRADUATE 2: Early Alzheimer’s Disease – 2 YEAR study to evaluate a potential disease modifying therapy, monthly subcutaneous injections versus placebo in patients between 50 and 90 years old with memory loss with 24 month open label extension. Patients need a study partner to attend some visits. (MMSE 22-28)

Eisai CLARITY: Early Alzheimer’s Disease – An 18-month randomized study to evaluate the safety and efficacy of an infused investigational medication vs. placebo in subjects 50-90 years of age with Mild Cognitive Impairment or early Alzheimer’s Disease. Visits are every 2 weeks, must have a study partner. 2-year Open label extension to follow for patients completing the double-blind study.  (MMSE 22-30)

Acadia: Parkinson’s Disease 063 – A 16-week Open label study of the Effects of treatment with Pimavanserin on Activities of Daily Living in subjects with Parkinson’s Disease Psychosis, must have a study partner

Impax: Parkinson’s Disease – A Randomized controlled study to compare the safety and efficacy of an oral drug with Immediate Release-Carbidopa-Levodopa in Parkinson’s disease patients with motor fluctuations.

Prilenia: Parkinson’s Disease – Study to Assess the Efficacy and Safety of Two Doses of Pridopidine versus Placebo for the Treatment of Levodopa Induced Dyskinesia.

Aptinyx: Parkinson’s Disease – A study to evaluate NYX-458 in subjects with Mild Cognitive Impairment associated with Parkinson’s Disease, must have a study partner and be between 50-80 years of age.

Acadia: Parkinson’s Disease 056 -A placebo-controlled study to evaluate Safety and Daytime Sedation in subjects with Parkinson’s Disease with Neuropsychiatric Symptoms with Pimavanserin or Low Dose Quetiapine. Must have a study partner and be at least 50 years old.

Satsuma: Acute Migraine – A randomized study to evaluate the Efficacy, Safety and Tolerability of inhaled Single Doses of STS101 in the Acute treatment of Migraine.

 

SUNRISE OFFICE NEUROLOGY – MS STUDIES
To participate or refer a patient –Call 954-475-8171 Ext 134 (Michele)

Clinical Coordinators: Michele Fistel, LPN, CCRC • Adriana Araujo,CCRC • Fanny Gully CRC

Novartis: EXCHANGE – Advancing Relapsing-Remitting MS – A 6 month open label study for a new oral medication for MS, patients wanting to switch from taking beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide (must have been on these medications for at least 3 months). Patients must have had a relapse in the last 12 months. Extension study to follow, for patients completing the 6-month study. Participants must be between 18-65 years old.